New anti-CD40L

'AT-1501, as a monotherapy and in conjunction with other immunosuppressive agents to prevent graft rejection in nonhuman primates. Encouragingly, AT-1501 promoted survival and function of islet and kidney allografts in cynomolgus and rhesus macaques, respectively, without evidence of thromboembolism.'

https://www.science.org/doi/10.1126/scitranslmed.adf6376